High levels of urinary pentosidine, an advanced glycation end product, in children with acute exacerbation of atopic dermatitis: relationship with oxidative stress.
Pentosidine is an advanced glycation end product formed by sequential glycation and oxidation. The formation of pentosidine is increased in diseases associated with oxidative stress, such as inflammatory conditions. The aim of the present study was to determine the urinary concentration of pentosidine in atopic dermatitis (AD) and its relationship to the inflammatory status of AD. Urine samples of 32 children with AD and 30 age-matched healthy control subjects were assayed for pentosidine, pyrraline (another advanced glycation end product formed by nonoxidative glycation), and 8-hydroxy-2'-deoxyguanosine (8-OHdG) (an established marker of oxidative stress). Of these 3 markers, urinary concentrations of pentosidine were significantly higher in patients with acute exacerbation of AD than in healthy controls and patients with stable AD. Urinary concentrations of 8-OHdG were significantly higher in AD patients with and without acute exacerbation than in healthy controls. Urinary pentosidine levels correlated significantly with those of 8-OHdG when all data of healthy controls and AD patients were plotted. In patients with acute exacerbation of AD, both urinary pentosidine and 8-OHdG significantly decreased after 7 to 9 days of treatment. Our findings in patients with acute exacerbation of AD suggest that pentosidine levels are partly determined by the prevailing oxidative stress in these patients.
Tsukahara
Hirokazu
H
Department of Pediatrics, Fukui Medical University, Japan.
Shibata
Rumiko
R
Ohta
Naoko
N
Sato
Shuko
S
Hiraoka
Masahiro
M
Ito
Setsuko
S
Noiri
Eisei
E
Mayumi
Mitsufumi
M
D000080242:8-Hydroxy-2'-Deoxyguanosine; D000208:Acute Disease; D001120:Arginine / Q000031:analogs & derivatives* / Q000652:urine*; D002648:Child; D002675:Child, Preschool; D003404:Creatinine / Q000097:blood; D003849:Deoxyguanosine / Q000031:analogs & derivatives* / Q000652:urine; D003876:Dermatitis, Atopic / Q000652:urine*; D005260:Female; D017127:Glycation End Products, Advanced / Q000652:urine*; D006801:Humans; D008239:Lysine / Q000031:analogs & derivatives* / Q000652:urine*; D008297:Male; D009646:Norleucine / Q000031:analogs & derivatives* / Q000652:urine; D018384:Oxidative Stress / Q000502:physiology*; D011758:Pyrroles / Q000652:urine
D017127:Glycation End Products, Advanced; D011758:Pyrroles; C059571:2-formyl-5-(hydroxymethyl)pyrrole-1-norleucine; D009646:Norleucine; D000080242:8-Hydroxy-2'-Deoxyguanosine; D001120:Arginine; D003404:Creatinine; C062187:pentosidine; D003849:Deoxyguanosine; D008239:Lysine